The size of the Liver Cancer Therapeutics Market in Europe was worth USD 185.34 million in 2021 and is estimated to be growing at a CAGR of 8.89% to reach USD 283.74 million by 2026. The European lung cancer diagnostics and therapeutics market will continue to avail favorable growth over the next few years. Invention and new product launches by the current and the new market players are the key factors projected to drive this market.
Studies on liver cancer therapeutics illustrate that liver cancer is more significant in men than in women and is generally seen in people over the age of 50. Treatment is based on tumor size, location, and overall health. A most common type of liver cancer, HCC is often unresectable, meaning that it cannot be removed surgically.
The growing incidence of liver cancer in the United Kingdom contributes well to the growth of the European liver cancer therapeutics market. As per the statistics published by the UK's Cancer research organization, nearly 5,736 new liver cancer cases were registered in the UK in 2015.
Strategies of prominent companies operating in Europe like mergers, collaborations and acquisitions, and R&D activities towards enhancements of novel therapies are projected to boost the market. Additionally, factors such as the increasing elderly population across the region, growing population base of cancer patients, technological developments in treatment and diagnosis procedures, rising number of hospitals and surgical centers, and the growing demand for minimally invasive cancer treatment techniques are driving the growth of the APAC liver cancer therapeutics market.
However, the high cost involved in cancer diagnosis and treatment procedures is acting as a major restraint for the market.
This research report has been segmented and sub-segmented into the following categories:
By Type:
By Therapeutics:
By End-User:
By Country:
Based on therapeutics, Hepatocellular Carcinoma is the largest segment for therapeutics type due to its high liver cancer prevalence.
Regionally, the U.K and Germany are estimated to be the leading markets in this region, while France is anticipated to witness the highest growth in the forecast period. The UK is expected to lead the market and is likely to dominate throughout the period. Sound knowledge levels about the early diagnosis and treatment of liver cancer, deep-rooted healthcare infrastructure boost the market.
The market in Germany and France are witnessed to grow with the highest CAGR rate and are the quickest developing countries of this region. Initially acquired advanced diagnostic tools and methods for liver cancer and a high base of pharmaceutical and biotechnology companies in this region are about to fuel this region's market.
Key players operating in the Europe Liver Cancer Therapeutics Market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Primary
5.1.2 Secondary
5.1.3 Benign Liver growths
5.2 By Therapeutics
5.2.1 Hepatocellular Carcinoma
5.2.2 Cholangio carcinoma
5.2.3 Hepatoblastoma
5.2.4 Targeted Therapy
5.3 By End-Users
5.3.1 Pediatrics
5.3.2 Adults
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Alnylam Pharmaceuticals Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 ImClone Systems Inc.
9.3 Onyx Pharmaceuticals Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Pfizer Inc.
9.6 ArQule Inc.
9.7 Jennerex Biotherapeutics Inc.
9.8 Celsion Corp.
9.9 Bayer Schering Pharma AG
9.10 4SC AG
9.11 Bristol-Myers Squibb Company
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
